S2: Ep8: AI Discoverability Is a Leadership Problem - Not a Content One

Most life science companies haven't checked whether AI recommends them. The ones that have are already pulling ahead.In this episode, Matt Wilkinson and Jasmine Gruia-Gray dig into the real commercial stakes of AI search visibility for life science tools and diagnostics companies - cutting through the AEO/GEO hype to ask the harder question: who in your organisation actually owns this?This episode is for: Marketing leaders, commercial directors, and CEOs at life science tools, diagnostics, and biotech companies who want to understand what AI discoverability actually means for pipeline and brand - and why it's a leadership problem, not a content one.KEY IDEA: AI discoverability is a leadership mandate, not a content strategy problem.What you will learn:Why 62% of life science exhibitors have never run the basic AI visibility test - and what that means commerciallyThe citation compression dynamic: AI surfaces roughly five brands per B2B category, and that list is hardening nowWhy absence from AI recommendations is categorically different from ranking fifth on GoogleThe structural AI citation advantage life science companies hold - and why most can't access itWhy framing this as a content project guarantees you hit a ceilingWhat the organisations that win will have in common: a named leader with cross-functional authorityKeywords: AI discoverability, life science marketing, AEO, GEO, answer engine optimisation, citation compression, AI search, B2B life science, biotech marketing, AI visibility, LLM search, AI overviewsWatch the full episode, subscribe to A Splice of Life Science Marketing, and explore Strivenn's AI readiness resources at strivenn.com.